Press coverage about Cytosorbents Corp (NASDAQ:CTSO) has been trending positive on Thursday, according to AlphaOne Sentiment Analysis. The research firm, a unit of Accern, identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytosorbents Corp earned a coverage optimism score of 0.38 on AlphaOne’s scale. AlphaOne also gave news coverage about the medical research company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted AlphaOne Sentiment’s rankings:
- CytoSorbents : 2017 – Propelling the Company to the “Next Level” (4-traders.com)
- Cytosorbents Corp (CTSO) Earns “Buy” Rating from Maxim Group (americanbankingnews.com)
- New Jersey Economic Development Authority : Industry Leaders to Offer Insight & Strategies for Taking Biotechnology Companies Public (4-traders.com)
- CytoSorbents 2017 – Propelling the Company to the “Next Level” (finance.yahoo.com)
- CTSO: Equity Raise, Cancer Applications, REFRESH I Data Upcoming (finance.yahoo.com)
Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down 2.15% during midday trading on Thursday, hitting $4.55. 103,487 shares of the stock traded hands. Cytosorbents Corp has a 52 week low of $4.00 and a 52 week high of $6.90. The firm’s 50-day moving average is $5.11 and its 200 day moving average is $5.45. The company’s market capitalization is $116.13 million.
Cytosorbents Corp (NASDAQ:CTSO) last released its earnings results on Friday, March 3rd. The medical research company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.06. The firm had revenue of $3.08 million for the quarter, compared to analyst estimates of $2.59 million. Cytosorbents Corp had a negative net margin of 120.04% and a negative return on equity of 193.13%. Equities analysts forecast that Cytosorbents Corp will post ($0.41) earnings per share for the current year.
Several equities research analysts have weighed in on CTSO shares. Maxim Group set a $10.00 price objective on shares of Cytosorbents Corp and gave the company a “buy” rating in a research report on Wednesday. B. Riley restated a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents Corp in a research report on Monday, March 6th. Aegis restated a “buy” rating on shares of Cytosorbents Corp in a research report on Tuesday, March 7th. Finally, HC Wainwright raised their price objective on shares of Cytosorbents Corp from $11.50 to $13.00 and gave the company a “buy” rating in a research report on Monday, March 6th. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $15.65.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065288/cytosorbents-corp-ctso-getting-favorable-media-coverage-study-finds.html
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.